Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal valued at up to €170 million plus royalties.Terms outlined in the letter of intent would consist of a €50 million upfront payment and […]
